Browse Category: Cancer Therapies

Dr. David Samadi is the Laser Surgereon Producing Medically Beneficial Results

Gaining customers in the robotics industry takes a firm dedication toward delivering excellence every time a new solution is rolled out into the marketplace. Dr. David Samadi is the Chief of Robotic Surgery at Lenox Hill Hospital. His career outlook is optimistic and he is focused on delivering positive results.Dr. David Samadi is a firm believer of the power of the internet, he’s become the forefront doctor that has connected internet based applications with the medical field. Through robotics and applying his knowledge Dr. Samadi is able to demonstrate the accuracy and effectiveness of internet based surgery performances. Performing surgeries with laparoscopic technology Dr. David Samadi has demonstrated effective methods toward helping rid the world of prostate cancer.

Even as a young child Dr. Samadi recalled in an interview how he would imagine that he would one day invent some type of device for the medical industry. Merging robots into the formula made it all come together in his later years.Every challenge that Dr.David Samadi takes under his wing is met with a efficient process that ensures that job gets done. Finding the right method to what Dr. David Samadi sets out to accomplish is tackled early, because Dr. Samadi has a strict policy of getting up early and setting out to accomplish his goals. Dr. Samadi has an interesting background and heritage. He hails from the Persian Jewish community of Iran and has went on to become the Chief Medical Correspondent AM 970 NYC, a popular New York city radio station.

In 1994 Dr. Samadi earned his medical degree from S.U.N.Y., Stony Brook School of Medicine. 2012 and 2013 were both great years for Dr. Samadi. In 2012 Dr.David Samadi earned $7.6 million and was awarded the title of highest paid Doctor in New York City. In 2013 he was appointed Professor of Urology at Hofstra North Shore-LIJ School of Medicine. Dr. Samadi is also considered to be a celebrity doctor.Throughout his career Dr. Samadi has proven that he is willing to rise through the ranks and step a firm tone in motion. The firm tone clearly expresses that with every surgery and every lecture that in medicine you have to be fully prepared to do the job at hand. Dr. Samadi enjoys teaching new students and showing them the benefits of connecting laser surgery with medicine to get medically beneficial results.

Dr. Clay Siegall is living legend of targeted cancer therapies

Today, it is largely taken for granted that if someone develops cancer, there’s a very good chance they’ll be able to survive, with a high degree of certainty, at the five-year survival benchmark. This is largely due to advancements that have taken place over the last 70 years. The advent of both radiation treatment and chemotherapy mark the beginning of modern cancer treatment, with real improvements in survivability seen across a wide swath of cancer types.

But in the mid-1980s, these advancements had become stagnant. Many types of cancers were no longer seeing the momentous gains and survivability that had been a staple of the ‘30s through the ‘60s. The cancer treatment industry needed to find new inroads to improving survivability.

Another aspect of the old treatment regimen was the sheer brutality of the side effects. The mainstays of cancer treatment had long been excision, radical surgery and both radiation and chemotherapy. All of these treatment modes had severe side effects associated with them. For example, people undergoing chemotherapy often times end up with permanent paresthesia, sensory deficits and other neurological conditions, including severe dementia. While not all patients experience these side effects at a high degree, they are bad enough that they represent a serious obstacle to the return to total health of the patient.

Beginning in the mid-‘90s, a man by the name of Clay Siegall became interested in a new field of cancer research called targeted cancer therapies. As a senior researcher at Bristol-Myers Squibb, Dr. Siegall first started working on a new class of targeted drugs called antibody drug conjugates. Antibody drug conjugates use the immune system to create antibodies, which are bound to cytotoxic agents. The major benefit of this method of cancer treatment is that there is no systemic release of the cytotoxic agents into the bloodstream, dramatically increasing the therapeutic window and allowing for highly lethal doses to be delivered directly to the site of the tumor. Whereas traditional chemotherapy may have taken six courses to reduce the tumor size by 25 percent, antibody drug conjugates can reduce the tumor size to nothing in just one treatment. And they have minimal associated side effects.